Kinfo
Celularity Inc. logo

Celularity Inc.

CELUNASDAQHealthcare·US · USD
$0.70
+0.01 (+1.92%)
Prices as of August 11, 2026 · market closed

Price

Key statistics

Valuation
Market cap20.27M USD
Enterprise value88.71M USD
Trailing P/E2.28
Forward P/E-1.25
PEG ratio-1.25
Price / sales0.77
Price / book0.00
Profitability
Gross margin-79.68%
Operating margin-492.15%
Profit margin24.39%
Return on assets-30.93%
Return on equity241.19%
Income (TTM)
Revenue26.55M USD
Gross profit6.48M USD
EBITDA-54.01M USD
Net income-91.80M USD
Diluted EPS-$3.59
Rev. growth (YoY)-77.40%
Balance sheet
Total cash6.17M USD
Total debt74.71M USD
Debt / equity-1.96
Current ratio0.15
Book value / share-$1.32
Cash flow (TTM)
Operating cash flow-13.25M USD
Levered free cash flow5.38M USD
Shares & price
Shares outstanding28.84M
Float18.87M
Held by institutions12.42%
Beta0.54
50-day MA$0.76
200-day MA$1.20
52-week high$4.31
52-week low$0.56
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-212.603.64+40.00%2026-03-310.590.66+11.86%2026-01-080.070.10+42.86%2024-01-02-0.03-0.50−1,566.67%2023-08-14-0.30-2.70−800.00%
About Celularity Inc.

Celularity Inc. is a biotechnology company that specializes in developing off-the-shelf placental-derived allogeneic cell therapies for cancer and other serious diseases. The primary focus of the company is to harness the unique properties of postpartum placental cells to create advanced cellular therapies. These innovative solutions aim to address unmet medical needs in immuno-oncology, infectious diseases, and degenerative diseases. Celularity Inc. leverages its proprietary technology platform to produce these cellular products, which are designed to enhance immune responses and offer therapeutic benefits. The company's work significantly impacts the healthcare and biotechnology sectors, where there is a continuous demand for transformative treatments that can improve patient outcomes. Situated at the forefront of cell therapy development, Celularity Inc. plays a pivotal role in advancing the understanding and application of cellular medicine, making its contributions highly valuable within the financial markets and the broader biopharmaceutical landscape.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Robert Joseph Hariri M.D., Ph.D.
Employees
115
Headquarters
Florham Park, NJ, United States

Frequently asked questions about Celularity Inc.